Hampton v. Insys Therapeutics, Inc.

319 F. Supp. 3d 1204
CourtDistrict Court, D. Nevada
DecidedJune 12, 2018
DocketCase No. 2:18–cv–00688–MMD–NJK
StatusPublished
Cited by20 cases

This text of 319 F. Supp. 3d 1204 (Hampton v. Insys Therapeutics, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Nevada primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hampton v. Insys Therapeutics, Inc., 319 F. Supp. 3d 1204 (D. Nev. 2018).

Opinion

MIRANDA M. DU, UNITED STATES DISTRICT JUDGE

Before the Court is Magistrate Judge Nancy J. Koppe's Report and Recommendation ("R & R" or "Recommendation") (ECF No. 20), recommending that this case be remanded for lack of subject matter jurisdiction. Defendants had until June 7, 2018, to file an objection. (Id.at 20.) To date, no objection to the R & R has been filed. Accordingly, the Court adopts the R & R with respect to remand.

1 This Court "may accept, reject, or modify, in whole or in part, the findings or recommendations made by the magistrate judge." 28 U.S.C. § 636(b)(1). Where a party timely objects to a magistrate judge's report and recommendation, then the court is required to "make a de novodetermination of those portions of the [report and recommendation] to which objection is made." 28 U.S.C. § 636(b)(1). Where a party fails to object, however, the court is not required to conduct "any review at all ... of any issue that is not the subject of an objection." Thomas v. Arn, 474 U.S. 140, 149, 106 S.Ct. 466, 88 L.Ed.2d 435 (1985). Indeed, the Ninth Circuit has recognized that a district court is not required to review a magistrate judge's report and recommendation where no objections have been filed. SeeUnited States v. Reyna-Tapia, 328 F.3d 1114 (9th Cir. 2003) (disregarding the standard of review employed by the district court when reviewing a report and recommendation to which no objections were made); see alsoSchmidt v. Johnstone, 263 F.Supp.2d 1219, 1226 (D. Ariz. 2003) (reading the Ninth Circuit's decision in Reyna-Tapia as adopting the view that district courts are not required to review "any issue that is not the subject of an objection"). Thus, if there is no objection to a magistrate judge's recommendation, then the court may accept the recommendation without review. See, e.g.,Johnstone, 263 F.Supp.2d at 1226 (accepting, without review, a magistrate judge's recommendation to which no objection was filed).

As noted, Defendants did not object to the R & R. Nevertheless, this Court finds it appropriate to engage in a de novoreview in order to determine whether to adopt the R & R. The Magistrate Judge recommends that this Court reject Defendant Insys Therapeutics, Inc.'s fraudulent misjoinder argument. Upon review of the R & R and filings in this case, the Court agrees with the R & R and will adopt the recommendation to remand for lack of subject matter jurisdiction.

It is hereby ordered that the Magistrate Judge's Report and Recommendation (ECF No. 20) is accepted and adopted. Defendant's motion to sever (ECF No. 18) is denied without prejudice. The Court declines to address the motion to dismiss (ECF No. 17) in light of this remand order. Plaintiff's motion to remand (ECF No. 19) is denied as moot.

*1207It is further ordered that this case is remanded.

REPORT AND RECOMMENDATION

Nancy J. Koppe, United States Magistrate Judge

Pending before the Court is an order for Defendant Insys Therapeutics, Inc. to show cause why this case should not be remanded for lack of subject matter jurisdiction. Docket No. 5. Defendant Insys filed a response indicating that subject matter jurisdiction exists and that remand would be improper. Docket No. 12; see also Docket No. 13 (corrected image). Plaintiff filed a response arguing that subject matter jurisdiction is absent. Docket No. 14.

For the reasons discussed below, the undersigned RECOMMENDS that this case be REMANDED for lack of subject matter jurisdiction. The undersigned also RECOMMENDS that Defendant Insys' recently-filed motion to dismiss (Docket No. 17) and motion to sever (Docket No. 18) be DENIED without prejudice to seeking relief in state court following remand. The undersigned further recommends that Plaintiff's recently-filed motion to remand (Docket No. 19) be DENIED as moot.

I. BACKGROUND

Plaintiff is the executor of the estate of Diana Hampton, who died following an overdose of the drug Fentanyl. Compl. ¶ 22 (Docket No. 1-1).1 Plaintiff filed a complaint in state court alleging that Defendant Steven Holper had been improperly providing Fentanyl to Ms. Hampton without a prescription and without a medically appropriate purpose. Id. at ¶¶ 17-20. Plaintiff alleges that Ms. Hampton would use a tool to open the Fentanyl canisters to access the drug and would then use a syringe to inject the Fentanyl into her arm. Id. at ¶ 21. Plaintiff alleges that, in improperly providing Fentanyl to Ms. Hampton, Defendant Holper is liable for wrongful death for negligently breaching his duty to provide proper medical treatment to Ms. Hampton. Id. at ¶¶ 28-41. Plaintiff also alleges a wrongful death claim against Defendant Holper for intentional and reckless conduct. Id. at ¶¶ 42-47.

Nine days after Plaintiff filed that complaint in state court, he filed an amended complaint that also names Insys as a defendant. Am. Compl. ¶ 3 (Docket No. 1-2). Plaintiff alleges that Insys is the manufacturer, marketer, and distributor of Fentanyl. See id. Plaintiff brings all of the above claims for wrongful death against both Defendant Holper and Defendant Insys. See id. at ¶¶ 29-48 (asserting causes of action against "all defendants").2 Plaintiff also brings three additional claims against Defendant Insys; causes of action for negligence, product liability design defect, and failure to warn. Id. at ¶¶ 49-71. With respect to the first of those causes of action, Plaintiff alleges that Defendant Insys was negligent in continuing to supply Fentanyl to Defendant Holper despite his history of medical malpractice, his history of overprescribing pain medications, and his highly suspicious orders. Id. at ¶¶ 51, 53, 58. Plaintiff also alleges that Defendant Insys misrepresented its compliance with its *1208

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
319 F. Supp. 3d 1204, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hampton-v-insys-therapeutics-inc-nvd-2018.